Ozempic: FDA-approved for the treatment of Type 2 Diabetes and to reduce the risk of major cardiovascular events (heart attack/stroke)
Why does activating the glucagon receptor not cause dangerous blood sugar increases
This rise is fuelling a parallel increase in obesity-related diseases, including type 2 diabetes [3], cardiovascular disease [4], and, critically, cancer
Concurrently, preclinical studies have shown that the co-administration of GIP and GLP-1 into the cerebral ventricles enhances additional weight reduction benefits [86]
Most patients lose some weight during this period, often five to ten pounds, but the primary work happening is biological: the medication is establishing its effect on appetite signaling and gastric emptying
Spacing injections at least one inch apart from previous injection sites gives skin time to recover between doses